26199-83-7

Basic information

• Product Name: N,N-DIMETHYL 3-NITROBENZENESULFONAMIDE
• Synonyms: N,N-DIMETHYL 3-NITROBENZENESULFONAMIDE;Benzenesulfonamide,N,N-dimethyl-3-nitro-
• CAS NO: 26199-83-7
• Molecular Formula: C₈H₁₀N₂O₄S
• Molecular Weight: 230.24
• Product Categories: blocks;NitroCompounds;Sulfonamides
• Mol File: 26199-83-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 120-121 °C(Solv: ethanol (64-17-5))
• Boiling Point: 363.9 °C at 760 mmHg
• Flash Point: 173.9 °C
• Appearance: /
• Density: 1.38 g/cm³
• Vapor Pressure: 1.75E-05mmHg at 25°C
• Refractive Index: 1.57
• PKA: -5.65±0.70(Predicted)
• CAS DataBase Reference: N,N-DIMETHYL 3-NITROBENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-DIMETHYL 3-NITROBENZENESULFONAMIDE(26199-83-7)
• EPA Substance Registry System: N,N-DIMETHYL 3-NITROBENZENESULFONAMIDE(26199-83-7)

Safety Data

• Hazardous Substances Data: 26199-83-7(Hazardous Substances Data)

Usage

General Description

N,N-DIMETHYL 3-NITROBENZENESULFONAMIDE is a chemical compound with the formula C8H10N2O4S. It is a derivative of sulfonamide, and is commonly used as an intermediate in the synthesis of pharmaceuticals. N,N-DIMETHYL 3-NITROBENZENESULFONAMIDE is a yellow crystalline solid that is soluble in organic solvents. It is used as a reagent in organic synthesis, particularly in the production of dyes, pigments, and pharmaceuticals. It is also known to have antibacterial and antifungal properties. However, it is important to handle N,N-DIMETHYL 3-NITROBENZENESULFONAMIDE with care as it may cause skin and eye irritation and should be handled in a well-ventilated area with appropriate protective equipment.

InChI:InChI=1/C8H10N2O4S/c1-9(2)15(13,14)8-5-3-4-7(6-8)10(11)12/h3-6H,1-2H3

Upstream product

• 124-40-3 dimethyl amine 
• 121-51-7 3-nitrobenzenesulphonyl chloride 
• 506-59-2 N,N-dimethylammonium chloride 
• 87-52-5 3-(Dimethylaminomethyl)indole 

Downstream Products

• 6274-18-6 3-amino-N,N-dimethylbenzenesulfonamide 

Relevant articles and documents

Controlled synthesis of N, N-dimethylarylsulfonamide derivatives as nematicidal agents

Gramine can be intelligently and efficiently supplied with N, N-dimethylamino group and then reacted with the corresponding sulfonyl chlorides to synthesize N, N-dimethylarylsulfonamides. We herein designed and controlled synthesis of N, N-dimethylarylsulfonamide derivatives, and first reported the results of the nematicidal activity of 15 title compounds 3a-o against Meloidogyne incongnita in vitro, respectively. Among all of the title derivatives, compounds 3a, 3c, 3k, and 3o exhibited potent nematicidal activity with median lethal concentration (LC50) values ranging from 0.22 to 0.26 mg/L. Most noteworthy, N, N-dimethyl-4-methoxyphenylsulfonamide (3c) and N, N-dimethyl-8-quinolinesulfonamide (3o) showed the best promising and pronounced nematicidal activity, with LC50 values of 0.2381 and 0.2259 mg/L, respectively.

Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models

Optimization of the previously reported benzothiazine analogue A led to the identification of compound 1, which showed anti-convulsant activity in two golden standard animal models of seizure, the MES and scPTZ models. Structure-activity relationship investigation of compound 1 revealed compounds 2, 6 and 19 as attractive anti-epileptic drug (AED) candidates with potent anticonvulsant effect in both the MES and scPTZ models. As these compounds are structurally different from existing AEDs, determination of their mechanism of actions could provide clues to understanding current therapy-resistant seizures. Moreover, these simple phenylsulfoneamide compounds could be good starting points for searching broad spectrum AEDs by such in vivo screening.

2 -MORPHOLINOPYRIMIDINES AND THEIR USE AS PI3 KINASE INHIBITORS

Morpholino pyrimidines of formula (I): wherein R1 is selected from -Y-R6 and -NR4R5; R2 is a N-containing monocyclic heteroaryl group which is selected from pyridyl, isoxazolyl, imidazolyl, pyrazolyl, pyrrolyl, thiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, oxazolyl, furanyl, thienyl, triazolyl and tetrazolyl and which is unsubstituted or substituted by halo, -CN, -NR10R11, -OR10, -C(O)R10, -NR10C(O)R11, - N(C(O)R11)2, -NR10C(O)NR10R11, -SO2R10R11, -SO2NR10R11, -C(=O)OR10, -C(=O)NR10R11, halo-C1 -C6 alkyl and unsubstituted C1-C12 alkyl; R3 is selected from H, C1-C6 alkyl and C1-C6 alkoxy; Y is selected from a direct bond, -(CR2)m-, C2-C6 alkenylene, C2-C6 alkynylene, -(CR2)p-O-(CR2) t-, -(CR2)p-NR-(CR2) t, -(CR2)p-NR-(CR2)n-C(O)-, -(CR2)p-NR-C(O)- (CR2)n-, -(CR2)p-C(O)-NR-(CR2) t, -(CR2)p-C(O)-(CR2)n-NR-(CR2)t,- and -(CR2)p- C(O)-(CR2)n-; R6 is selected from an unsaturated 5- to 12-membered carbocyclic or heterocyclic ring, a saturated 5-, 6- or 7- membered N-containing heterocyclic group which is unsubstituted or substituted, C1-C6 alkyl, -NR2, -OR, -NR(CO)R and - C(O)NR2; R4 and R5, which are the same or different, are both C1-C6 alkyl which is unsubstituted or substituted, or R4 and R5 together form, with the nitrogen atom to which they are attached, a saturated 5-, 6- or 7- membered N-containing heterocyclic group which is unsubstituted or substituted; each R, which are the same or different when more than one is present in a given group, is independently H, C1-C6 alkyl which is unsubstituted or substituted or a 5- to 12-membered aryl or heteroaryl group which is unsubstituted or substituted; R10 and R11, which are the same or different, are independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and C3-C8 cycloalkyl; n is 0 or an integer of 1 to 6; m is an integer of 1 to 6; p is 0 or an integer of 1 to 6; and t is 0 or an integer of 1 to 6, with the proviso that t is an integer of 2 to 6 when R6 is linked to Y through a constituent O or N atom of R6; and the pharmaceutically acceptable salts thereof, subject to various provisos, have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour, particularly that associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described